Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 40

Sort by

Sort Order Select

Journal Articles

Preservation of the fecal microbiome is associated with reduced severity of graft-versus-host disease

Blood (2022) 140 (22): 2385–2397.

https://doi.org/10.1182/blood.2021015352

Published: 2022

Includes: Supplemental data

Journal Articles

Prospective Study of Peri-Transplant Use of Sorafenib As Remission Maintenance for FLT3-ITD Patients Undergoing Allogeneic Transplantation

Keith W. Pratz, MD, Ivana Gojo, MD, Judith E. Karp, MD, Leo Luznik, MD, B. Douglas Smith, MD, Richard J Jones, MD, Jackie Greer, RN, Christopher Gocke, MD, Maria R. Baer, MD, Vu H. Duong, MD, John J Wright, MD PhD, Michelle A. Rudek, PharmD, PhD, Ashkan Emadi, MD, PhD, Mark J. Levis, MD PhD

Blood (2015) 126 (23): 3164.

https://doi.org/10.1182/blood.V126.23.3164.3164

Published: 2015

Journal Articles

Phase 2 Trial of the Farnesyltransferase Inhibitor Tipifarnib in Previously Untreated Older Adults with AML and Baseline Presence of a Specific 2-Gene Expression Signature Ratio

Jeffrey E Lancet, MD, Eric Feldman, MD, Matthew C Foster, MD, Ivana Gojo, MD, Olatoyosi Odenike, MD, Rami S. Komrokji, MD, Roger Strair, MD, PhD, Scott H. Kaufmann, MD, PhD, Roland Knoblauch, MD, PhD, J. D. Karkera, PhD, John J Wright, MD, PhD, Judith E. Karp, MD

Blood (2012) 120 (21): 1508.

https://doi.org/10.1182/blood.V120.21.1508.1508

Published: 2012

Journal Articles

Randomized Phase II Trial of Timed-Sequential Therapy (TST) with Flavopiridol (Alvocidib), Ara-C and Mitoxantrone (FLAM) Versus “7+3” for Adults Ages 70 Years and Under with Newly Diagnosed Acute Myeloid Leukemia (AML)

Joshua F. Zeidner, MD, Jonathan M. Gerber, MD, Amanda Blackford, Mark Litzow, MD, Matthew C. Foster, MD, Lawrence E. Morris, Jr., MD, Ivana Gojo, MD, Jeffrey E. Lancet, MD, Prithviraj Bose, MD, Raoul Tibes, MD, Stephen A. Strickland, MD, MSCI, Jacqueline M Greer, RN, Michelle Drye, Kevin Meads, Austin Doyle, MD, Richard F Little, MD, MPH, John J Wright, MD, PhD, Judith E. Karp, MD

Blood (2012) 120 (21): 47.

https://doi.org/10.1182/blood.V120.21.47.47

Published: 2012

Journal Articles

Multi-institutional phase 2 clinical and pharmacogenomic trial of tipifarnib plus etoposide for elderly adults with newly diagnosed acute myelogenous leukemia

Blood (2012) 119 (1): 55–63.

https://doi.org/10.1182/blood-2011-08-370825

Published: 2012

Includes: Supplemental data

Journal Articles

Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma

Blood (2011) 117 (22): 5827–5834.

https://doi.org/10.1182/blood-2010-10-312603

Published: 2011

Journal Articles

Phase 1 and pharmacokinetic study of bolus-infusion flavopiridol followed by cytosine arabinoside and mitoxantrone for acute leukemias

Judith E. Karp, B. Douglas Smith, Linda S. Resar, Jacqueline M. Greer, Amanda Blackford, Ming Zhao, Dwella Moton-Nelson, Katrina Alino, Mark J. Levis, Steven D. Gore, Biju Joseph, Hetty Carraway, Michael A. McDevitt, Lorena Bagain, Karen Mackey, Janet Briel, L. Austin Doyle, John J. Wright, Michelle A. Rudek

Blood (2011) 117 (12): 3302–3310.

https://doi.org/10.1182/blood-2010-09-310862

Published: 2011

Journal Articles

Randomized Phase II Study of Two Schedules of Flavopiridol (Alvocidib, F) Given as Timed Sequential Therapy (TST) Wtih Ara-C and Mitoxantrone (FLAM) for Adults with Newly Diagnosed, Poor-Risk Acute Myelogenous Leukemia (AML)

Judith E. Karp, MD, John M. Pagel, MD, PhD, B. Douglas Smith, MD, Jacqueline M Greer, RN, D. Michelle Drye, RN, Kelly M. Smith, MD, Kathleen Dorcy, RN, John J Wright, MD, PhD, L. Austin Doyle, MD, PhD, Elizabeth Garrett-Mayer, PhD, Elihu H. Estey, MD

Blood (2010) 116 (21): 186.

https://doi.org/10.1182/blood.V116.21.186.186

Published: 2010

Journal Articles

Determining Why and Which Clinicians Order Serum Protein Electrophoresis (SPEP), Subsequent Diagnoses Based On Indications, and Clinical Significance of Routine Follow-up: a Study of Patients with Monoclonal Gammopathy of Undetermined Significance (MGUS).

Leah M Doyle, B.S., Jacob D Gundrum, M.S., John P. Farnen, MD, Linda J. Wright, CTR, Jo Ann I Kranig, RHIT, Ronald S. Go, MD

Blood (2009) 114 (22): 4883.

https://doi.org/10.1182/blood.V114.22.4883.4883

Published: 2009

Journal Articles

The Duffy-null state is associated with a survival advantage in leukopenic HIV-infected persons of African ancestry

Hemant Kulkarni, Vincent C. Marconi, Weijing He, Michael L. Landrum, Jason F. Okulicz, Judith Delmar, Dickran Kazandjian, John Castiblanco, Seema S. Ahuja, Edwina J. Wright, Robin A. Weiss, Robert A. Clark, Matthew J. Dolan, Sunil K. Ahuja

Blood (2009) 114 (13): 2783–2792.

https://doi.org/10.1182/blood-2009-04-215186

Published: 2009

Includes: Supplemental data

Journal Articles

Active oral regimen for elderly adults with newly diagnosed acute myelogenous leukemia: a preclinical and phase 1 trial of the farnesyltransferase inhibitor tipifarnib (R115777, Zarnestra) combined with etoposide

Blood (2009) 113 (20): 4841–4852.

https://doi.org/10.1182/blood-2008-08-172726

Published: 2009

Includes: Supplemental data

Journal Articles

Proportions of Bone Marrow Lymphocyte Subsets Predict Survival in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma Independent of International Prognostic Index

Luke D. Zurbriggen, Jacob D Gundrum, M.S., Sai Ravi Kiran Pingali, M.B.B.S., Gorden G. Zeng, M.D., Austin Zeng, Linda J. Wright, Ronald S. Go, MD

Blood (2008) 112 (11): 2834.

https://doi.org/10.1182/blood.V112.11.2834.2834

Published: 2008

Journal Articles

A 2-gene classifier for predicting response to the farnesyltransferase inhibitor tipifarnib in acute myeloid leukemia

Mitch Raponi, Jeffrey E. Lancet, Hongtao Fan, Lesley Dossey, Grace Lee, Ivana Gojo, Eric J. Feldman, Jason Gotlib, Lawrence E. Morris, Peter L. Greenberg, John J. Wright, Jean-Luc Harousseau, Bob Löwenberg, Richard M. Stone, Peter De Porre, Yixin Wang, Judith E. Karp

Blood (2008) 111 (5): 2589–2596.

https://doi.org/10.1182/blood-2007-09-112730

Published: 2008

Includes: Supplemental data

Journal Articles

A Two-Gene Classifier for Predicting Response to the Farnesyltransferase Inhibitor Tipifarnib in Acute Myeloid Leukemia.

Mitch Raponi, PhD, Jeffrey E. Lancet, MD, Hongtao Fan, PhD, Lesley Dossey, PhD, Grace Lee, MSc, Ivana Gojo, MD, Eric J. Feldman, MD, Jason Gotlib, MD, Lawrence E. Morris, MD, Peter L. Greenberg, MD, John J. Wright, MD, Jean-Luc Harousseau, MD, Bob Lowenberg, MD, Richard M. Stone, MD, Peter De Porre, MD, Yixin Wang, PhD, Judith E. Karp, MD

Blood (2007) 110 (11): 1445.

https://doi.org/10.1182/blood.V110.11.1445.1445

Published: 2007

Journal Articles

Interstitial Lung Disease in Patients with Diffuse Large B-Cell Lymphoma Receiving CHOP-Based Chemotherapy Is Associated with the Use of Rituximab.

Ronald S. Go, MD, Kevin M. Riggle, Sue A. Beier-Hanratty, MD, Jacob D. Gundrum, MS, Jonean E. Schroeder, Linda J. Wright, Brian A. Manske, MD

Blood (2007) 110 (11): 3435.

https://doi.org/10.1182/blood.V110.11.3435.3435

Published: 2007

Journal Articles

Phase I Trial of Suberoylanilide Hydroxamic Acid (SAHA) + Bortezomib (Bort) in Relapsed Multiple Myeloma (MM) Patients (pts).

Ashraf Badros, S. Philip, R. Niesvizky, O. Goloubeva, C. Harris, J. Zweibel, J. Wright, A. Burger, S. Grant, M.R. Baer, M.J. Egorin

Blood (2007) 110 (11): 1168.

https://doi.org/10.1182/blood.V110.11.1168.1168

Published: 2007

Journal Articles

Anti-Angiogenic Effects of Sorafenib in Relapsed Chronic Lymphocytic Leukemia: Correlative Studies of a Phase 2 Clinical Trial.

Sowjanya Reganti, MD, Edith Kabba, PhD, Wendy Stock, MD, John J. Wright, MD, PhD, John E. Godwin, MD, MS, Ameet R. Kini, MD, PhD

Blood (2007) 110 (11): 4726.

https://doi.org/10.1182/blood.V110.11.4726.4726

Published: 2007

Journal Articles

Update of a Phase I Study of Sorafenib in Patients with Refractory/Relapsed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome.

John Delmonte, Jr., MD, Hagop M. Kantarjian, MD, Michael Andreeff, MD/PhD, Stefan Faderl, MD, John J. Wright, MD, Weiguo Zhang, MD, Marina Konopleva, MD/PhD, Srdan Verstovsek, MD/PhD, Gautam Borthakur, MD, Farhad Ravandi, MD, Jorge Cortes, MD

Blood (2007) 110 (11): 893.

https://doi.org/10.1182/blood.V110.11.893.893

Published: 2007

Journal Articles

In Vivo Correlates of Response for Phase I Trial of Oral Tipifarnib (T) Combined with Oral Etoposide (E) for Adults Age ≥ 70 with Newly Diagnosed Acute Myelogenous Leukemia (AML) Who Are Not Candidates for Traditional Cytotoxic Chemotherapy (TCC).

Rebecca M. Ricklis, MS, Judith E. Karp, MD, Eric J. Feldman, MD, Suzanne Galkin, BA, Jacqueline M. Greer, RN, Valerie Ironside, CRNP, Kim Mirjafary, Timothy D. Talbot, BA, Lawrence E. Morris, MD, John J. Wright, MD, PhD, Scott H. Kaufmann, MD, PhD

Blood (2007) 110 (11): 914.

https://doi.org/10.1182/blood.V110.11.914.914

Published: 2007

Journal Articles

Final Update of Phase I-II Study of the Farnesyltransferase Inhibitor Tipifarnib in Combination with Idarubicin and Cytarabine for Patients with Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome.

John Delmonte, Jr., MD, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD, Zeev Estrov, MD, Farhad Ravandi, MD, Srdan Verstovsek, MD/PhD, Susan O’Brien, MD, Charles A. Koller, MD, Stefan Faderl, MD, Deborah A. Thomas, MD, John J. Wright, MD, Jorge Cortes, MD

Blood (2007) 110 (11): 441.

https://doi.org/10.1182/blood.V110.11.441.441

Published: 2007

NARROW

Preservation of the fecal microbiome is associated with reduced severity of graft-versus-host disease

Prospective Study of Peri-Transplant Use of Sorafenib As Remission Maintenance for FLT3-ITD Patients Undergoing Allogeneic Transplantation

Phase 2 Trial of the Farnesyltransferase Inhibitor Tipifarnib in Previously Untreated Older Adults with AML and Baseline Presence of a Specific 2-Gene Expression Signature Ratio

Randomized Phase II Trial of Timed-Sequential Therapy (TST) with Flavopiridol (Alvocidib), Ara-C and Mitoxantrone (FLAM) Versus “7+3” for Adults Ages 70 Years and Under with Newly Diagnosed Acute Myeloid Leukemia (AML)

Multi-institutional phase 2 clinical and pharmacogenomic trial of tipifarnib plus etoposide for elderly adults with newly diagnosed acute myelogenous leukemia

Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma

Phase 1 and pharmacokinetic study of bolus-infusion flavopiridol followed by cytosine arabinoside and mitoxantrone for acute leukemias

Randomized Phase II Study of Two Schedules of Flavopiridol (Alvocidib, F) Given as Timed Sequential Therapy (TST) Wtih Ara-C and Mitoxantrone (FLAM) for Adults with Newly Diagnosed, Poor-Risk Acute Myelogenous Leukemia (AML)

Determining Why and Which Clinicians Order Serum Protein Electrophoresis (SPEP), Subsequent Diagnoses Based On Indications, and Clinical Significance of Routine Follow-up: a Study of Patients with Monoclonal Gammopathy of Undetermined Significance (MGUS).

The Duffy-null state is associated with a survival advantage in leukopenic HIV-infected persons of African ancestry

Active oral regimen for elderly adults with newly diagnosed acute myelogenous leukemia: a preclinical and phase 1 trial of the farnesyltransferase inhibitor tipifarnib (R115777, Zarnestra) combined with etoposide

Proportions of Bone Marrow Lymphocyte Subsets Predict Survival in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma Independent of International Prognostic Index

A 2-gene classifier for predicting response to the farnesyltransferase inhibitor tipifarnib in acute myeloid leukemia

A Two-Gene Classifier for Predicting Response to the Farnesyltransferase Inhibitor Tipifarnib in Acute Myeloid Leukemia.

Interstitial Lung Disease in Patients with Diffuse Large B-Cell Lymphoma Receiving CHOP-Based Chemotherapy Is Associated with the Use of Rituximab.

Phase I Trial of Suberoylanilide Hydroxamic Acid (SAHA) + Bortezomib (Bort) in Relapsed Multiple Myeloma (MM) Patients (pts).

Anti-Angiogenic Effects of Sorafenib in Relapsed Chronic Lymphocytic Leukemia: Correlative Studies of a Phase 2 Clinical Trial.

Update of a Phase I Study of Sorafenib in Patients with Refractory/Relapsed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome.

In Vivo Correlates of Response for Phase I Trial of Oral Tipifarnib (T) Combined with Oral Etoposide (E) for Adults Age ≥ 70 with Newly Diagnosed Acute Myelogenous Leukemia (AML) Who Are Not Candidates for Traditional Cytotoxic Chemotherapy (TCC).

Final Update of Phase I-II Study of the Farnesyltransferase Inhibitor Tipifarnib in Combination with Idarubicin and Cytarabine for Patients with Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only